Assessing the Influence of Subsequent Immunotherapy on Overall Survival in Patients with Unresectable Stage III Non–Small Cell Lung Cancer from the PACIFIC Study

BACKGROUND: Historically, the standard of care for patients with unresectable, Stage III non–small cell lung cancer had been concurrent chemoradiotherapy. However, outcomes had been poor, with approximately 15% to 32% of patients alive at 5 years. In the placebo-controlled Phase III A PACIFIC trial,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ouwens, Mario, Darilay, Annie, Zhang, Yiduo, Mukhopadhyay, Pralay, Mann, Helen, Ryan, James, Dennis, Phillip A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406163/
https://www.ncbi.nlm.nih.gov/pubmed/34484473
http://dx.doi.org/10.1016/j.curtheres.2021.100640

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406163/
https://www.ncbi.nlm.nih.gov/pubmed/34484473
http://dx.doi.org/10.1016/j.curtheres.2021.100640

Ejemplares similares